Filing Details

Accession Number:
0001615219-16-000128
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-03-15 16:53:39
Reporting Period:
2016-03-11
Filing Date:
2016-03-15
Accepted Time:
2016-03-15 16:53:39
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1615219 Flex Pharma Inc. FLKS () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1543245 Longwood Fund Ii, L.p. C/O Flex Pharma, Inc.
800 Boylston Street
Boston MA 02199
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-03-11 89,680 $7.00 2,786,944 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Footnotes
  1. On March 11, 2016, Longwood Fund III, L.P. ("Longwood Fund III") purchased 89,680 shares of Common Stock of the Issuer (the "Common Shares")
  2. Longwood Fund III owns 89,680 Common Shares and Longwood Fund II, L.P. ("Longwood Fund II") owns 2,697,264 Common Shares.
  3. Longwood Fund II GP, LLC is the ultimate General Partner of Longwood Fund II and Longwood Fund III GP, LLC is the ultimate General Partner of Longwood Fund III. Christoph Westphal, M.D., Ph.D., Richard Aldrich and Michelle Dipp, M.D., Ph.D. (collectively, the "Managers") are managers of Longwood Fund II GP, LLC and Longwood Fund III GP, LLC, and, as such, may be deemed to have shared voting and dispositive power with respect to the Issuer's securities held by Longwood Fund II and Longwood Fund III (the "Longwood Shares"). Each of the Managers disclaims beneficial ownership of the Longwood Shares, except to the extent of their respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of Section 16 or for any other purpose.